Initiate the open-label extension for the MONARCH study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- January 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Planned initiation 1H 2021”
What we found
Evidence strength A What the grades mean
The company initiated the SWALLOWTAIL open-label extension study, which serves as the extension for the MONARCH study, in January 2021, meeting the first-half 2021 deadline.
-
A Stoke Therapeutics, Inc. 10-Q filed 2021-08-10
“In January 2021, we initiated enrollment and dosing in our SWALLOWTAIL Open Label Extension (OLE) study of STK-001 for children and adolescents with Dravet syndrome.” ✓ confirmed on the page
-
A Stoke Therapeutics, Inc. 10-K filed 2022-03-10
“Patients who participated in the MONARCH study and meet study entry criteria are eligible to continue treatment in SWALLOWTAIL” ✓ confirmed on the page
Market reaction: the shares moved -1.6% against the S&P 500 over the three sessions around the disclosure (9 Aug 2021 to 12 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- Open-label extension for MONARCH study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Stoke Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-STOK-021619 · Corrections policy